For Research Use Only. Not for Clinical Use.

Creative Biolabs is a leading service provider that focuses on half-life extension for drug development. Based on our advanced platforms and extensive experience, now we can provide a series of half-life extension services against thrombocytopenic purpura for our clients all over the world.

Introduction of Half-life Extended Drug

With the advantages of high efficacy, few side effects, as well as low immunogenicity, therapeutic peptides, and proteins present great potentials for diseases treatment. Furthermore, the novel fusion protein drugs retain the biological activity of the original protein and have the effect of prolonging the half-life of the drug.

The distribution of the modified fusion protein-drug in the body is generally targeted, which significantly improves the efficacy of the drug and reduces the toxicity of the drug. Fusion protein drugs are mostly degraded by hydrolysis with proteases in organs and tissues, so they have a long half-life. Some of the amino acids and small peptide fragments produced by protease degradation are excreted by the kidneys, and some enter the endogenous amino acid pool for the re-synthesis of endogenous substances.

Methods to Improve the Pharmacokinetic Behavior of Small Peptides and Proteins

• Increase the size and hydrodynamic radius of peptides and proteins.
• Increase the negative surface charge of peptides and proteins.
• Increase the serum protein level of proteins and peptides by connecting albumin and immunoglobulin.

Fig 1. Activated platelets in blood smear and red blood cells.

Application of Half-life Extended Drug in Thrombocytopenic Purpura

Idiopathic thrombocytopenic purpura, also known as immune thrombocytopenia (ITP), is the disorder that leads to symptoms, such as purple bruises and tiny reddish-purple dots. Thrombocytopenic purpura usually occurs when your immune system mistakenly attacks and destroys platelets. In adults, this may be caused by infection with HIV, hepatitis, or Helicobacter pylori. In children, the disease is more often caused by viral diseases, such as mumps or flu. A GCSF-IgG1 Fc fusion protein, with a half-life of 3.5 days, has been developed to treat thrombocytopenic purpura by activating the intracellular transcriptional pathway that leads to increased platelet production through the TPO receptor. In addition, more fusion protein drugs are being developed for the treatment of thrombocytopenic purpura.

Creative Biolabs has been a long-term expert in the field of drug development. As a pioneer and the undisrupted global leader in half-life extension, we offer a variety of solutions to improve your productivity and streamline your research processes. If you are interested in our products or services, please do not hesitate to contact us for more detailed information.